Research Papers

7 of 7 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Salles G; Długosz-Danecka M; Ghesquières H; Jurczak W.
Expert Opin Biol Ther (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Immune checkpoint inhibition in COVID-19: risks and benefits.
Pezeshki PS; Rezaei N.
Expert Opin Biol Ther (Unknown)
Published: 2021
1/6 Transparent
Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies.
Whitehead M; Wickremasinghe S; Osborne A; Van Wijngaarden P; Martin KR.
Expert Opin Biol Ther (Unknown)
Published: 2018
2/6 Transparent
Funding Declared
Golimumab for the treatment of ulcerative colitis.
Flamant M; Paul S; Roblin X.
Expert Opin Biol Ther (Unknown)
Published: 2017
2/6 Transparent
Funding Declared
The use of the NIS reporter gene for optimizing oncolytic virotherapy.
Miller A; Russell SJ.
Expert Opin Biol Ther (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Ever closer to a prophylactic vaccine for HCV.
Swadling L; Klenerman P; Barnes E.
Expert Opin Biol Ther (Unknown)
Published: 2013
2/6 Transparent
Funding Declared
The role of reverse genetics in the development of vaccines against respiratory viruses.
Marsh GA; Tannock GA.
Expert Opin Biol Ther (Unknown)
Published: 2005